TIGT Therapies Digital Summit
The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings.
As evidence of TIGIT’s clinical potential builds, the TIGIT Therapies Digital Summit brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI.
Hear from leaders in TIGIT development from Merck, Compugen, iTeos Therapeutics, Agenus and more!
Core challenges must still be addressed by the community, such as:
|Investigating the TIGIT pathway, ligands, and modes of action|
|Optimizing biomarker strategy to identify optimal patient populations and indications|
|Rationalizing combination strategy to leverage the TIGIT mechanism for maximum therapeutic benefit.|
The TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research. Gain access to 1:1 time with leaders in TIGIT development, and take away tangible learnings with dedicated panel discussions and poster sessions throughout the event.
In such a fast-paced industry, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field, and to accelerate the safe development of TIGIT therapies with maximum clinical impact.
For more details about the program, speaker faculty or pricing and discounts, download the brochure.